Xencor (NASDAQ:XNCR) Price Target Raised to $19.00

Xencor (NASDAQ:XNCR) had its target price increased by Royal Bank Of Canada from $18.00 to $19.00 in a report published on Thursday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on XNCR. Bank of America lowered Xencor from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $23.00 to $12.00 in a report on Wednesday, September 3rd. Wedbush reissued an “outperform” rating and issued a $26.00 price target on shares of Xencor in a research report on Tuesday, September 2nd. Barclays raised Xencor from an “underweight” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $23.00 in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Tuesday, October 14th. Finally, Cantor Fitzgerald increased their price target on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Thursday. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and an average price target of $24.63.

Xencor Price Performance

NASDAQ:XNCR opened at $13.90 on Thursday. Xencor has a 1-year low of $6.92 and a 1-year high of $27.24. The company has a 50-day moving average of $11.71 and a 200 day moving average of $9.69. The firm has a market cap of $991.39 million, a PE ratio of -5.79 and a beta of 0.99.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.64. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $21.00 million during the quarter, compared to analyst estimates of $29.73 million. During the same quarter in the previous year, the business posted ($0.71) EPS. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. Sell-side analysts anticipate that Xencor will post -3.68 EPS for the current fiscal year.

Institutional Trading of Xencor

Several large investors have recently bought and sold shares of the stock. State of Wyoming acquired a new position in Xencor during the 1st quarter valued at approximately $34,000. Hantz Financial Services Inc. grew its holdings in shares of Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,449 shares during the last quarter. CWM LLC increased its position in shares of Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 2,231 shares during the period. Finally, Farther Finance Advisors LLC purchased a new position in Xencor in the 3rd quarter worth $44,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.